Abstract
Objective:The loss of expression of syndecansyndecan-1 is associated with poor prognosis in many types of human cancer. The objective of this study was to evaluate the relation between syndecan-1 immunoexpression and several clinicopathological parameters in a subset of colorectal carcinoma (CRC) patients.Methods:Pathology tissue blocks of 202 primary tumors, 41 adenomas, and 37 normal colonic mucosae were used in this study. The cases diagnosed in the period 1995–2015 was included in the study. Immunohistochemistry analysis was performed using anti-CD138/syndecan-1 (B-A38) mouse monoclonal antibody. A semiquantitative method was used to score the syndecan-1 expression based on an evaluation of the percentage and intensity of the membranous and cytoplasmic expression. The data collected from Pathology Department at King Abdulaziz University Hospital, Jeddah, Saudi Arabia. This is a retrospective cohort study that was conducted from July 2018 until August 2019.Results:Loss of syndecan-1 immunoexpression was observed in 72 (42.6%), 5 (12.2%), and 3 (8.1%) cases of CRC, adenomas, and normal mucosae, respectively. Low expression of syndecan-1 showed an association with nodal (p=0.003) and distant (p=0.001) metastasis, lymphovascular invasion (p=0.001), and tumor recurrence (p=0.006). Low syndecan-1 expression were associated with short overall survival (OS) (log rank 4.019, p=0.045) and disease-free survival (DFS) probabilities (log rank 4.748, p=0.029).Conclusion:Loss of syndecan-1 immunoexpression is associated with metastatic potential, tumor recurrence and shorter survival in CRC and is considered a potential biomarker of poor prognosis in CRC patients.
Highlights
Colorectal carcinoma (CRC) is a common gastrointestinal cancer in Saudi Arabia
The patients’ data and histopathological material were collected from the Pathology Department at King Abdulaziz University Hospital, Jeddah, Saudi Arabia for the cases diagnosed in the period 1995–2015
Immunohistochemistry: Immunocytochemistry was performed by utilizing CD138/syndecan-1 (B-A38) Mouse Monoclonal Antibody
Summary
Colorectal carcinoma (CRC) is a common gastrointestinal cancer in Saudi Arabia. It ranks as the first type among Saudi men and third among Saudi women.[1] The molecular changes involved in CRC carcinogenesis are not yet clear. The mortality rate of CRC is high and caused primarily by invasion and metastasis of the tumor. Investigation of the molecular changes or triggering factors associated with invasion and metastasis in CRC is important and may contribute to changes in therapeutic approaches in the future. Pak J Med Sci January - February 2021 Vol 37 No 1 www.pjms.org.pk 114
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
